Key Points The USPTO issued a Notice of Allowance for claims covering oral tablet compositions of elraglusib, Actuate’s investigational GSK-3β inhibitor. The allowance includes the…
November 02, 2026
October 23, 2026
BioLineRx and Hemispherian Report Encouraging GLIX1 Combination Results in Ovarian Cancer Models
Key Points GLIX1 enhanced the activity of three PARP inhibitors in laboratory studies of HR-proficient ovarian cancer cells. In a mouse model using patient-derived ovarian…
Key Points A pooled analysis of 111 patients with metastatic breast cancer found that an immune marker measured after treatment was associated with clinical outcomes….
Key Points Personalis commercially launched Real-Time Variant Tracker as an optional addition to its NeXT Personal molecular residual disease test report. The supplemental results track…
Key Points Actinium Pharmaceuticals appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026. He brings more than 20 years of…
October 14, 2026
Verastem Jumps as VS-7375 Posts 50% Response Rate in Pancreatic Cancer, Backed by $250 Million Raise and CEO Succession Plan
Verastem, Inc. (NASDAQ: VSTM) shares rose about 19% on Wednesday, putting the stock at the top of the PRISM Women’s Health Index. The jump followed…
October 13, 2026
Oncolytics Expands Pelareorep Patent Portfolio, Targeting Protection Into the Late 2040s
Key Points Oncolytics has secured a new patent in several countries covering pelareorep’s use as a cancer immunotherapy, with a corresponding U.S. patent expected soon….
October 13 is Metastatic Breast Cancer Awareness Day, which spotlights the stage of breast cancer that still has no cure and the emerging companies working…
October 08, 2026
Myriad Genetics Advances Prostate Cancer Biomarker Through SOPHiA GENETICS Collaboration
Key Points Myriad Genetics is partnering with SOPHiA GENETICS to advance its prostate cancer-specific genomic instability score, or PrGIS, in precision oncology work involving AstraZeneca….
Key Points BioLineRx and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia. Both presentations are scheduled for November…
September 14, 2026
FDA Approves Telix’s Pixclara for Glioma Brain Cancer Imaging
Key Points The FDA approved Telix Pharmaceuticals’ Pixclara® for PET imaging in patients with glioma, a form of brain cancer. Pixclara is the first FDA-approved…
September 10, 2026
Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer
Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep…